Hologic, Inc.

Hologic, Inc. HOLX

Dividend Summary

There have not been any declared dividends recently.

Latest Dividends
Summary Previous dividend Next dividend
Per share
Declaration date
Ex-div date
Pay date

Enter the number of Hologic, Inc. shares you hold and we'll calculate your dividend payments:

Previous Payment
Next Payment
Forecast Accuracy
We have not made any dividend predictions for Hologic, Inc.
Dividend Yield Today
The dividend yield is calculated by dividing the annual dividend payment by the prevailing share price
The table below shows the full dividend history for Hologic, Inc.
Status Type Decl. date Ex-div date Pay date Decl. Currency Forecast amount Decl. amount Accuracy
There are no Hologic, Inc. dividends.
Year Amount Change
2006 0.0c
2007 0.0c
2008 0.0c
2009 0.0c
2010 0.0c
2011 0.0c
2012 0.0c
2013 0.0c
2014 0.0c
2015 0.0c
2016 0.0c
2017 0.0c
2018 0.0c
2019 0.0c
2020 0.0c
2021 0.0c
2022 0.0c
2023 0.0c
2024 Sign Up Required

Hologic, Inc. Optimized Dividend Chart

The chart below shows the optimized dividends for this security over a rolling 12-month period.
Dividend Yield Today
Optimized Yield
Sign Up Required
52 Week High
0.0% on 14 July 2023
52 Week Low
0.0% on 14 July 2023
Next Ex-Div-Date Countdown
Sign Up Required

About Hologic, Inc.

Hologic, Inc., incorporated on January 18, 1990, is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Company sells and services its products through a combination of direct sales and service personnel and a network of independent distributors and sales representatives.

Diagnostics Products

The Company's diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases (STDs), chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Company offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1) for use on Panther instrument system. The three viral load assays are marketed in Europe. Aptima products integrate technologies, including target capture technology, Transcription Mediated Amplification (TMA), hybridization protection assay (HPA) and dual kinetic assay (DKA) technologies to produce refined amplification assays.

The Company develops and manufactures the Procleix family of assays, which are marketed and sold around the world by Grifols, blood screening collaborator, under Grifols' trademarks. The Procleix family of assays includes the Ultrio and Ultrio Plus assays, which detect HIV-1, HCV, and HBV in donated blood, plasma, organs and tissues; the Ultrio Elite assay, which simultaneously detects HIV-1, HIV-2, HBV and HCV in donated blood, plasma, organs and tissues; the Hepatitis E Virus (HEV) assay, which detects the HEV in donated blood, plasma, organs and tissues; the West Nile Virus (WNV) assay, which detects WNV in donated blood, plasma, organs and tissues, and the Parvo/Hepatitis A Virus (HAV) assay, which detects the Parvovirus and HAV in donated blood, plasma, organs and tissues.

The Company's instrumentation includes the Tigris system, an integrated, fully-automated testing instrument for high-volume laboratories, which is approved for use with a number of Aptima and Procleix assays; the Panther instrument system, an integrated, fully-automated testing instrument capable of serving both high-volume and low-volume laboratories, and semi-automated direct tube sampling (DTS) instruments, which are used to run a number of infectious disease assays. The Company also utilizes Tomcat instrument, a fully-automated general purpose instrument designed for pre-analytical sample processing by eliminating the inefficient and error-prone activities associated with manually transferring samples from one tube to another. The Company also uses Invader chemistry platform, a deoxyribonucleic acid (DNA) probe-based system for highly sensitive detection of specific nucleic acid sequences and ThinPrep System for cervical cancer screening.

Breast Health Products

The Breast Health products include a portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD), for mammography and minimally invasive breast biopsy devices, breast biopsy site markers and breast biopsy guidance systems. The breast imaging platform, Dimensions, utilizes a technology called tomosynthesis to produce three dimensional (3D) images that show multiple contiguous slice images of the breast, which are referred to as the Genius 3D Mammography exam, as well as conventional Two Dimensional (2D) full field digital mammography images.

The Company offers minimally invasive products for breast biopsy and biopsy site marking. Its breast biopsy portfolio includes two types of tethered vacuum-assisted breast biopsy products, the Automated Tissue Excision Collection (ATEC) and Eviva devices. The ATEC device can be used under all standard imaging guidance modalities (stereotactic x-ray, ultrasound, magnetic resonance imaging (MRI) and molecular breast imaging) whereas its Eviva device is used under stereotactic x-ray guidance. It also offers the Celero device, a non-tethered (no separate console), vacuum-assisted, spring-loaded, disposable core biopsy device, which is used under ultrasound-guidance.

GYN Surgical Products

The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The NovaSure system involves a minimally invasive procedure that allows physicians to treat women suffering from abnormal uterine bleeding. The system consists of a disposable device and a controller that delivers radio frequency (RF), energy to ablate the endometrial lining of the uterus in order to eliminate or reduce the patient's bleeding. The NovaSure disposable device is a hand-held, single-use device that incorporates a flexible gold-plated mesh electrode used to deliver the RF energy during the NovaSure procedure. The MyoSure system is designed to provide hysteroscopic removal of fibroids located just below the lining of the uterus, as well as uterine polyps and other pathology within the uterus.

Skeletal Health Products

The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems. The discovery x-ray bone densitometers incorporate dual-energy x-ray technology to assess bone density of the fracture sites, the spine and hip. The mini C-arm systems are used by orthopedic surgeons to assist in performing minimally invasive surgical procedures on a patient's extremities, such as the hand, wrist, knee, foot and ankle.

The Company competes with Becton, Dickinson and Company, Roche Diagnostics Corporation, Qiagen, Medix Biochemical, General Electric Company, Siemens, Koninklijke Philips N.V., Planmed Oy, Carestream Health, Inc., Fujifilm Holdings Corporation, I.M.S., Toshiba Corporation, Danaher Corporation, Sanarus Technologies, LLC, Intact Medical Corporation, Boston Scientific Corporation, The Cooper Companies, Inc., Minerva Surgical, Inc., Medtronic and F. Hoffmann-La Roche Ltd.

Pharmaceuticals & Biotechnology
United States
Share Price
$77.69 (yesterday's closing price)
Shares in Issue
233 million
Market Cap
The Consecutive Annual Dividend Increases - the number of years this company has been increasing its dividends
Market Indices
S&P 500
No articles found